• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Varian and Icon Group Partner to Extend Commitment to Global Cancer Care

    4/27/21 4:15:00 PM ET
    $VAR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $VAR alert in real time by email

    PALO ALTO, Calif., April 27, 2021 /PRNewswire/ -- Varian (NYSE:VAR), a Siemens Healthineers company, has signed an agreement with Australia's Icon Group to provide 30 linear accelerators and associated treatment software to help tackle the growing global cancer burden. This agreement further strengthens the global partnership between Varian and Icon Group, together increasing access to care across regional and underserviced areas in Australia and Asia.

    The order is comprised of a variety of Varian linear accelerators and software including Halcyon™, TrueBeam®, and HyperArc™. These systems will be installed in new and existing Icon cancer centers in Australia to increase capacity and broaden patient access, as well as in cancer centers in Singapore and China.

    "We are extremely proud of our global partnership with Varian, which continues to help meet our long-term goal of increasing access to care. This investment helps to address the cancer burden in rural and regional Australia and underserved communities in Singapore and China," said Mark Middleton, CEO of Icon Group. "It's great to see progress being made on the path to a world where cancer is no longer a burden; where people have every opportunity to fight cancer no matter where they live."

    Icon continues to play a paramount role in the development of radiation oncology treatments and has been an early adopter of Varian technologies over the years, including the first in Australasia to install the Varian Halcyon radiotherapy system and first in Australia to install and treat with HyperArc technology – benefitting patients with multiple tumors in the brain. Icon Group is also a member of the Varian Adaptive Intelligence™ Consortium, alongside other international institutions, to collaboratively develop clinical and technical aspects of Ethos™ therapy and wider radiation therapy treatments and techniques that will continue to evolve cancer care. 

    "We are honored to be selected once again by Icon Group to provide Varian radiotherapy and radiosurgery systems for its cancer centers around the world," said Chris Toth, CEO, Varian, a Siemens Healthineers company. "As the cancer burden continues to rise, we are proud to work with our global partners at Icon Group to expand access to advanced cancer care to achieve a world without fear of cancer."

    About Varian

    At Varian, a Siemens Healthineers company, we envision a world without fear of cancer. For more than 70 years, we have developed, built and delivered innovative cancer care technologies and solutions for our clinical partners around the globe to help them treat millions of patients each year. With an Intelligent Cancer Care approach, we are harnessing advanced technologies like artificial intelligence, machine learning and data analytics to enhance cancer treatment and expand access to care. Our 11,000 employees across 70 locations keep the patient and our clinical partners at the center of our thinking as we power new victories in cancer care. Because, for cancer patients everywhere, their fight is our fight. For more information, visit http://www.varian.com and follow @VarianMedSys on Twitter.

    Press Contact

    Lynne Tran

    Corporate Communications

    [email protected]

    Investor Relations Contact

    Siemens Healthineers Investor Relations

     

     

    Cision View original content:http://www.prnewswire.com/news-releases/varian-and-icon-group-partner-to-extend-commitment-to-global-cancer-care-301278361.html

    SOURCE Varian

    Get the next $VAR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VAR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VAR
    SEC Filings

    View All

    SEC Form 15-12B filed by Varian Medical Systems, Inc.

    15-12B - VARIAN MEDICAL SYSTEMS INC (0000203527) (Filer)

    4/26/21 8:41:51 AM ET
    $VAR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 25-NSE filed by Varian Medical Systems, Inc.

    25-NSE - VARIAN MEDICAL SYSTEMS INC (0000203527) (Subject)

    4/15/21 10:56:56 AM ET
    $VAR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form S-8 POS filed by Varian Medical Systems, Inc.

    S-8 POS - VARIAN MEDICAL SYSTEMS INC (0000203527) (Filer)

    4/15/21 9:28:52 AM ET
    $VAR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $VAR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Icon Group First in World to Adopt New Multi-Disciplinary Oncology Information System from Varian

    PALO ALTO, Calif., Aug. 5, 2021 /PRNewswire/ -- Varian, a Siemens Healthineers company, announced today that cancer patients in Australia will be the first in the world to benefit from streamlined, coordinated cancer care facilitated by an upcoming release of the ARIA® oncology information system (OIS) with new multi-disciplinary functionality. Australia's Icon Group will become the first in the world to deploy this new system, which is scheduled for release in Australia and other global sites in early 2022. Icon plans to go live with its first location in 2022. After a successful deployment, the new ARIA system will serve as Icon's next-generation platform for enhancing clinical operatio

    8/5/21 11:00:00 AM ET
    $VAR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Varian and Icon Group Partner to Extend Commitment to Global Cancer Care

    PALO ALTO, Calif., April 27, 2021 /PRNewswire/ -- Varian (NYSE:VAR), a Siemens Healthineers company, has signed an agreement with Australia's Icon Group to provide 30 linear accelerators and associated treatment software to help tackle the growing global cancer burden. This agreement further strengthens the global partnership between Varian and Icon Group, together increasing access to care across regional and underserviced areas in Australia and Asia. The order is comprised of a variety of Varian linear accelerators and software including Halcyon™, TrueBeam®, and HyperArc™. These systems will be installed in new and existing Icon cancer centers in Australia to increase capacity and broaden

    4/27/21 4:15:00 PM ET
    $VAR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    PTC Set to Join S&P 500; Lattice Semiconductor & Progyny to Join S&P MidCap 400; Domtar to Join S&P SmallCap 600

    NEW YORK, April 15, 2021 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 effective prior to the open of trading on Tuesday, April 20: S&P MidCap 400 constituent PTC Inc. (NASD:PTC) will replace Varian Medical Systems Inc. (NYSE:VAR) in the S&P 500, and Lattice Semiconductor Co. (NASD:LSCC) will replace PTC in the S&P MidCap 400. Siemens Healthineers AG (XETR: SHL) acquired Varian Medical Systems Inc. in a deal that closed today, April 15. Progyny Inc. (NASD:PGNY) will replace Domtar Corp. (NYSE:UFS) in the S&P MidCap 400, and Domtar will replace NIC Inc. (NASD:EGOV) in the S&P SmallCap 600. S&P 500 constituent Tyler T

    4/15/21 6:03:00 PM ET
    $PGNY
    $VAR
    $LSCC
    Misc Health and Biotechnology Services
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Semiconductors

    $VAR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Balser Jeffrey R. returned 2,824 units of Common Stock to the company, decreasing direct ownership by 100% to 0 units

    4 - VARIAN MEDICAL SYSTEMS INC (0000203527) (Issuer)

    4/16/21 8:07:02 PM ET
    $VAR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4: BUTEL JEAN LUC returned 4,048 units of Common Stock to the company, decreasing direct ownership by 100% to 0 units

    4 - VARIAN MEDICAL SYSTEMS INC (0000203527) (Issuer)

    4/16/21 8:05:39 PM ET
    $VAR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4: DUGAN REGINA E returned 12,396 units of Common Stock to the company, decreasing direct ownership by 100% to 0 units

    4 - VARIAN MEDICAL SYSTEMS INC (0000203527) (Issuer)

    4/16/21 8:04:17 PM ET
    $VAR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $VAR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Varian Medical Systems downgraded by UBS Group

    UBS Group downgraded Varian Medical Systems from to In-Line

    3/1/21 9:05:48 AM ET
    $VAR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Varian Medical Systems downgraded by UBS Group

    UBS Group downgraded Varian Medical Systems from Buy to In-Line

    2/23/21 9:04:05 AM ET
    $VAR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    UBS Group reiterated coverage on Varian Medical Systems with a new price target

    UBS Group reiterated coverage of Varian Medical Systems with a rating of In-Line and set a new price target of $1.00

    2/5/21 9:00:01 AM ET
    $VAR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $VAR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed

    SC 13G/A - VARIAN MEDICAL SYSTEMS INC (0000203527) (Subject)

    2/10/21 11:57:25 AM ET
    $VAR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care